Eva Lumbreras González-rekin lankidetzan egindako argitalpenak (4)

2019

  1. Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation

    Annals of Hematology, Vol. 98, Núm. 9, pp. 2151-2162

2018

  1. Transcriptomic rationale for synthetic lethality-targeting ERCC1 and CDKN1A in chronic myelomonocytic leukaemia

    British Journal of Haematology, Vol. 182, Núm. 3, pp. 373-383

2012

  1. Imatinib therapy of chronic myeloid leukemia restores the expression levels of key genes for DNA damage and cell-cycle progression

    Pharmacogenetics and Genomics, Vol. 22, Núm. 5, pp. 381-388

2009

  1. Effects of imatinib mesylate on normal bone marrow cells from chronic myeloid leukemia patients in complete cytogenetic response

    Leukemia Research, Vol. 33, Núm. 1, pp. 170-173